- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03861442
Front-End Processing 3.0 (FEP3)
September 6, 2021 updated by: MED-EL Elektromedizinische Geräte GesmbH
Front-End Processing 3.0 - Noise Reduction, Transient Reduction, Scene Classifier
MED-EL Cochlear Implants (CI) provide auditory sensations via electrical stimulation of the auditory pathways for severely to profoundly hearing-impaired individuals who obtain little or no benefit from acoustic amplification in the best aided condition.
Front-end processing of acoustic signals picked up by the audio processor is routinely applied to provide optimal hearing performance under varying listening conditions.
Automatic Sound Management (ASM) was introduced by MED-EL with the TEMPO+ audio processor.
With the new SONNET 2 audio processor, ASM 3.0 was implemented and the features noise reduction, transient reduction and an automatic scene classifier were added.
This study will investigate the impact of ASM 3.0 as implemented in the SONNET 2 on CI users' speech performance and their subjective quality of hearing.
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Actual)
20
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Bayern
-
Würzburg, Bayern, Germany, 97080
- Klinik und Poliklinik für Hals-, Nasen- und Ohrenkrankheiten, plastische und ästhetische Operationen
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Post-lingually deafened adult cochlear implant users with a MED-EL device
Description
Inclusion Criteria:
- A minimum of 18 years old
- Experienced user (≥ 6 months) of a MED-EL cochlear implant (CI; C40+ and later model)
- Experienced user of a MED-EL SONNET audio processor (≥ 6 months)
- Post-lingual onset of bilateral severe to profound sensory-neural hearing loss
- Unilateral CI user
- A minimum of 10 active electrodes
- A minimum of 40% speech recognition in the Freiburg Monosyllables test in quiet at 65 dB sound pressure level (SPL; at the last time tested)
- Fluent in German (the language of the test centre)
- Signed and dated Informed Consent Form before the start of any study-specific procedure.
Exclusion Criteria:
- Lack of compliance with any inclusion criteria
- CI user with contralateral hearing equal to or better than 60 dB (PTA measured at 500, 1000, and 2000Hz)
- User with electric-acoustic stimulation (EAS; user of an EAS audio processor)
- Implanted with C40X and C40C
- Implanted with an Auditory Brainstem Implant or Split electrode array
- Known allergic reactions to components of the investigational medical device
- Unstable psychological status
- Anything that, in the opinion of the Investigator, would place the subject at increased risk or preclude the subject's full compliance with or completion of the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Speech in noise
Time Frame: 8 weeks
|
Oldenburg Sentence Test in noise (S0N0)
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Speech in noise
Time Frame: 8 weeks
|
Oldenburg Sentence Test in noise (S0N0)
|
8 weeks
|
Speech in quiet
Time Frame: 8 weeks
|
Freiburg Monosyllabic test in quiet
|
8 weeks
|
Speech in noise
Time Frame: 8 weeks
|
Oldenburg Sentence Test in noise (S0N0T0)
|
8 weeks
|
Speech in noise
Time Frame: 8 weeks
|
Oldenburg Sentence Test in noise (S0, ±N45, ± N135)
|
8 weeks
|
Quality of hearing
Time Frame: 8 weeks
|
Hearing Implant Sound Quality Index
|
8 weeks
|
Quality of hearing
Time Frame: 8 weeks
|
Questionnaire: The Speech, Spatial and Qualities of Hearing Scale (SSQ12; short version, 12 items) with a scale range 0 (worst) to 10 (best)
|
8 weeks
|
Device handling
Time Frame: 8 weeks
|
Audio Processor Satisfaction Questionnaire (APSQ) with a scale range 0 (worst) to 10 (best)
|
8 weeks
|
Subjective Ratings
Time Frame: 8 weeks
|
Adaptive CAtegorical Listening Effort Scaling (ACALES); Subjectively perceived listening Effort is evaluated using a 14-step scale contains eight labelled categories (from "effortless" to "extremely strenuous" and "noise only")
|
8 weeks
|
Subjective Ratings
Time Frame: 8 weeks
|
Subjective Sound Quality Rating
|
8 weeks
|
User Satisfaction
Time Frame: 8 weeks
|
A product specific questionnaire will be used to gain user satisfaction on the new audio processor and individual setting preferences
|
8 weeks
|
Device Use
Time Frame: 8 weeks
|
Data Logging
|
8 weeks
|
Sound Quality and Quality of hearing
Time Frame: 8 weeks
|
Hearing Implant Sound Quality Index 19 (HISQUI19) with a 7-point rating scale (never to always)
|
8 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
April 1, 2019
Primary Completion (ACTUAL)
March 5, 2020
Study Completion (ACTUAL)
March 5, 2020
Study Registration Dates
First Submitted
February 28, 2019
First Submitted That Met QC Criteria
March 1, 2019
First Posted (ACTUAL)
March 4, 2019
Study Record Updates
Last Update Posted (ACTUAL)
September 8, 2021
Last Update Submitted That Met QC Criteria
September 6, 2021
Last Verified
September 1, 2021
More Information
Terms related to this study
Other Study ID Numbers
- MED-EL_CRD_2017_06
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cochlear Implants
-
Centre Hospitalier Universitaire DijonCompletedUnilateral Cochlear Implants | Bilateral Cochlear ImplantsFrance
-
MED-EL Elektromedizinische Geräte GesmbHNot yet recruiting
-
MED-EL Elektromedizinische Geräte GesmbHHannover Medical SchoolCompleted
-
Advanced Bionics AGCompletedCochlear ImplantsFrance
-
Hospices Civils de LyonRecruiting
-
Father Flanagan's Boys' HomeCompletedCochlear ImplantsUnited States
-
Hospices Civils de LyonCompletedCochlear ImplantsFrance
-
Sophie McKennyUniversity of CambridgeEnrolling by invitationCochlear ImplantsUnited Kingdom
-
Hospices Civils de LyonCompletedCochlear ImplantsFrance
-
Centre Hospitalier Universitaire de NiceRecruitingCochlear ImplantsFrance